Member Info for dallo

Snowking

The Nasdaq Biotechnology Index is up 32% over the past 6 months.

Puretech shares unchanged over past 6 months.

Still no news on the Chair and CEO appointments being made permanent which is really unusual in a Public Company.

It has gone strangely quiet over the past 2 weeks with low trading volumes and no further buying by Tang Capital.

Maybe next week will be our week to join the Biotech party.

ATB.

Another China Tariff climbdown by TACO Trump after dire warnings from Central Banks and others of impending recession and collapse in the markets as inflation rises again and US Consumer Confidence plummets with the US Government shut for past 2 weeks.

Thankfully markets are steady this morning but what a way to run the World's largest economy...by early morning social media posts!

With Cyptocurrency and AI Stocks futures looking very scary for a Monday Stock Markets opening, we could be looking at major falls in prices and possibly a crash.

Thankfully Puretech has cash and no debt particularly with Debt Markets in a panic

Rumours of an emergency FED meeting on Sunday .

Trump and his mad tariffs , Government shutdown, National Guards in Chicago, Portland and LA and corruption at every level of his Administration has destroyed confidence in the US as a safe investment location.

The rush to gold is the canary in the coal mine.

A correction is long way overdue so maybe a flushing out of the excess may be good but the millions of retail investors and institutions punting with debt is frightening.

Escape

If it is 10 more years, please contact me with the good news ...via a seance!

JSB

The question I have is why are we having pullbacks in the share price after recent positive news.

Surely the opposite should be happening and buyers moving in at these depressed levels.

The stock markets have been on fire over past 6 months but Puretech is down again.

Very strange.

Snowking

The optimist in me thought that after recovering strongly to 144p last Friday on positive newsflow , the SP had finally broken the downward trend line.

Sadly the 7% drop since then has dampened my good feelings.

Snowking

That explains the weakness in Puretech's shares today.

Golfnut

Well done on Spruce Bio.

I had a similar touch on Immupharma which went from 1.75p to 17p in a week but sold around 8p.

Immupharma has little or no cash and registered a patent on its immune therapies which have yet to be clinically trialled but attracted the hordes on speculative utterances from its management.

Poor old Puretech is largely ignored by the market even after some extremely positive recent news .

Only 65 trades reported today so far .

Hopefully we will have our day in the sun soon.

I have been waiting for 6 years now so let's go!!!

Down we go again...well it was fun while it lasted!

Seriously if the SP cannot hold 140p in the midst of recent developments then we are in trouble.

Oldbutnowisa

The key pointer to a possible imminent offer is that the company still hasn't appointed a permanent Chair or CEO and Liu and Lyne look like short term appointments to oversee the sale.

Either the company confirms their respective appointments as permanent within the next few weeks or appoints new senior management .

I don't see either of the above two managerial options been exercised so the sale option remains likely.

However nothing is certain with Puretech and I could be very wrong on the above assumptions.

Nonetheless I feel something is about to unfold very soon particularly with Tang Capital continuing to stake build.

ATB

Rock

The link is to Puretech's May Presentation

BMS share price surge is also due to the Orange Moron's usual TACO retreat on Pharma tariffs after he realised that 50m Americans would be paying twice the normal exorbitant prices for drugs and possibly leading to serious consequences for patients.

Cobenfy revenues for 3rd Quarter should be available in next 2 weeks

Also Nordic Capital can now come back into the game after its 6 month exclusion period ends tomorrow to make another approach.

Apologies

FT Article appeared last week but only got some traction today along with other positive announcements from BMS

BMS share price surging in New York after it agrees to sell its blockbuster Schizophrenia drug , Cobenfy , in International markets at the same pricing levels as the US ( $22,500 a year) following Trump meeting and his insistence on US drug prices being the same as in International markets.

Report today in the FT expects Cobenfy to be approved by the UK early next year and to be available on the NHS despite the high costs given the rising rates of Schizophrenia related illnesses.

Another major boost for Puretech and not yet spotted by the market today.

Will have to spend c£20/25m to get another 6% or so of the shares , 1 should say

Rock

Tang Capital cannot stop at an ineffectual 4% but must get to c10% or more to have any influence with major Institutional Investors holding c70% and founders , directors , managers and connected parties holding c10%.

Tang will have spend another £20/25m or get another 6%.

They better hurry up while the sale lasts!!

Theta

Beat me to it...Doh!!

LYT-100 or Deupirfenidone , a deuterated form of Pirfenidone, was acquired by Puretech in 2019 from Auspex Pharma ( now part of Teva Pharma) and included 6 US and 26 Foreign patents expiring in 2028 with a probable extension to 2035.

Puretech also has 1 US Patent and 1 US Patent in -license from Auspex expiring in 2035 for further formulations and methods.

Following Puretechs extensive R&D on LYT-100 over the past 5 years, a further 13 US and 39 patents are pending both in relation to Deupirfenidone

with IPF and a number of other therapeutic conditions.

It is interesting to see ex Teva Pharma people involved in Celea Pharma.

Jamgoo

That is indeed a major coincidence

I declared to the discussion board here that I held 225 ,000 shares as well after recent buys.

I hope you do very well .

ATB